恶性疾病患者凝血纤溶分子标志物的研究  

Study of molecular markers of coagulation and fibrinolysis in patients with maligant diseases

作　　者：周合冰[1] 刘复强[1] 闫树旭[2] 翟艳玲[1] 张娟[2] 王丽[2] 李利红[3] 

机构地区：[1]首都医科大学附属北京同仁医院,北京100730 [2]首都医科大学血液病学系北京通州区潞河医院,北京101149 [3]首都医科大学血液病学系北京朝阳医院,北京100020

出　　处：《中国卫生检验杂志》2008年第2期302-305,共4页Chinese Journal of Health Laboratory Technology

摘　　要：目的:测定恶性疾病患者凝血纤溶分子标志物,观察急性白血病、淋巴瘤、实体瘤三种恶性疾病凝血、纤溶系统改变的临床意义。方法:选择同期恶性肿瘤47例,其中急性白血病患者27例(其中初治21例和复发组6例),淋巴瘤患者10例;实体瘤患者10例;对照组为30例健康人。取空腹外周静脉血,3.8%枸橼酸钠抗凝,采用酶联免疫双抗体夹心法测定血浆组织因子(TF)、血浆凝血酶-抗凝血酶复合物(TAT)、血浆组织型纤溶酶原激活物(t-PA)、血浆纤溶酶原激活物抑制物(PAI-1)。结果:急性白血病、淋巴瘤、实体瘤三组的TF值均高于对照组,有统计学意义,淋巴瘤组的TF值高于急性白血病组,差异有显著性统计学意义;急性白血病组、淋巴瘤组、实体瘤组的TAT高于对照组,并达到统计学意义;急性白血病、淋巴瘤、实体瘤三组的t-PA值均高于对照组,有显著统计学意义;实体瘤组t-PA值高于急性白血病组;急性白血病组及实体瘤PAI-1均高于对照组,有统计学意义。结论:急性白血病、淋巴瘤、实体瘤存在相似的凝血和纤溶异常。Objective：The antigens as molecular markers of coagulation and fibrinolysis systems were measured in patients with malignant tumors in order to investigate their changes among the patients with acute leukemia（AL）,malignant lymphoma（ML） and solid tumors.Methods：By enzyme-linked immunosorben assay（ELISA）,4 plasma molecular markers of the coagulation and fibrinolysis systems were measured in 30 healthy volunteers and 47 cases of malignant tumors that included 27 patients with AL,in which 21 newly-diagnosed AL,6 relapsed cases,10 patients with ML and 10 patients with solid tumor.Their blood samples were taken from their veins at fasting in the morning,with anticoagulant of 3.8% sodium citrate.These molecular markers of coagulation and fibrinolytic system were as followings： tissue factor（TF）,Thrombin——antithrombin complexes（TAT）,tissue-type plasminogen activator（t-PA）,plasminogen activator inhibitor-1（PAI-1）.Results：1.The levels of TF in 47 cases of malignant tumors were all significantly higher than that in control group,TF level in ML group was significantly higher than that in AL group;2.TAT levels in the group of AL,ML group and solid tumor group were all significantly higher than that in control group respectively;3.The levels of t-PA in 3 groups of malignant tumors were all significantly higher than that in control group,the solid tumor group was significantly higher than AL group.4.The PAI-1 levels in AL group or in solid tumor group were significantly higher than that in control group.Conclusion：In patients with acute leukemia,lymphoma and solid tumor,there are the similar coagulation and fibrinolysis aberrancy that are predisposed to blood coagulation and inhibition of fibrinolysis.

关 键 词：恶性疾病 凝血 纤维蛋白溶解 

分 类 号：R730[医药卫生—肿瘤]